Nobumasa Mizuno

10PUBLICATIONS
70CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsHaematological tumoursPredictive and prognostic markersOncology and carcinogenesis not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Apr 13, 2026
Randomized phase III trial of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable pancreatic cancer in geriatric patients: JCOG2101C (PRESTIGE study).

Yusuke Sano, Masato Ozaka, Shuichi Aoki

|Jul 28, 2025
Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611): A Randomized, Open-Label, Phase II/III Trial.

Akihiro Ohba, Masato Ozaka, Junki Mizusawa

|Apr 10, 2025
Clinicomolecular Profile and Efficacy of Human Epidermal Growth Factor Receptor 2 (HER2)-Targeted Therapy for HER2-Amplified Advanced Biliary Tract Cancer.

Kanae Inoue, Yoshiaki Nakamura, Bennett Caughey

|Mar 07, 2025
Impact of clinically diagnosed liver cirrhosis in patients with intrahepatic cholangiocarcinoma treated with systemic chemotherapy: a subgroup analysis of JCOG1113.

Mao Okada, Eiichiro Suzuki, Chigusa Morizane

|Jan 17, 2025
Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial.

Alicia F C Okines, Giuseppe Curigliano, Nobumasa Mizuno

|Aug 28, 2024
Clinical utility of BRCA and ATM mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancer.

Kentaro Sudo, Yoshiaki Nakamura, Makoto Ueno

Pageof 2

Frequent Collaborators

5 joint publications

Naohiro Okano

4 joint publications

Yoshiaki Nakamura

4 joint publications

Masafumi Ikeda

3 joint publications

Tanios Bekaii-Saab